Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
4033 clinical trials for this condition and its sub-types, 313 tagged with Autoimmune disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disease
-
Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types
4 sub-types
- Autoimmune disorder of central nervous system 2 trials · 874 incl. sub-types Sub-types →
- Autoimmune disorder of peripheral nervous system 0 trials · 194 incl. sub-types Sub-types →
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Autoimmune retinopathy 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Celiac disease 79 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune gastritis 3 trials
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related sclerosing cholangitis 0 trials
-
Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types
13 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Autoimmune thyroid disease 8 trials · 62 incl. sub-types Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune polyendocrinopathy 3 trials · 11 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types Sub-types →
- Autoimmune pancreatitis 3 trials Sub-types →
- Autoimmune primary ovarian failure 1 trial
- IgG4-related sclerosing cholangitis 0 trials
- Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome 0 trials
- Autoimmune oophoritis 0 trials
- Insulin autoimmune syndrome 0 trials
- Primary hypophysitis 0 trials Sub-types →
-
CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types
1 sub-type
- Multiple sclerosis 765 trials · 852 incl. sub-types Sub-types →
-
Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types
3 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Neonatal dermatomyositis 0 trials
-
Lupus erythematosus 39 trials · 548 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types
3 sub-types
- Sjogren syndrome 166 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Benign lymphoepithelial lesion of salivary gland 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Evans syndrome 19 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Antiphospholipid syndrome 58 trials · 59 incl. sub-types
4 sub-types
- Primary antiphospholipid syndrome 4 trials
- Catastrophic antiphospholipid syndrome 1 trial
- Familial antiphospholipid syndrome 0 trials
- Secondary antiphospholipid syndrome 0 trials Sub-types →
-
Autoimmune bullous skin disease 7 trials · 55 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 27 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types
14 sub-types
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related kidney disease 1 trial
- IgG4-related retroperitoneal fibrosis 1 trial Sub-types →
- IgG4-related aortitis 0 trials
- IgG4-related mediastinitis 0 trials
- IgG4-related mesenteritis 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- IgG4-related pachymeningitis 0 trials
- IgG4-related sclerosing cholangitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- IgG4-related thyroid disease 0 trials
- Cutaneous pseudolymphoma 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
- Primary cutaneous plasmacytosis 0 trials
-
Rheumatic fever 16 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Type III hypersensitivity disease 3 trials · 6 incl. sub-types
2 sub-types
- Serum sickness 3 trials
- Arthus reaction 0 trials
-
Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types
7 sub-types
- Autoimmune inner ear disease 2 trials
- Autoimmune uveitis 2 trials
- Cogan syndrome 0 trials
- IgG4-related dacryoadenitis and sialadenitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- Autoimmune retinopathy 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types
6 sub-types
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Libman-Sacks endocarditis 0 trials
- Autoimmune atherosclerosis 0 trials
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Autoimmune vasculitis 0 trials Sub-types →
- Rheumatic pulmonary valve disease 0 trials
-
Susac syndrome 2 trials
-
Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types
-
Phacolytic glaucoma 1 trial
-
Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types
6 sub-types
- Neonatal lupus erythematosus 1 trial
- Neonatal antiphospholipid syndrome 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
- Neonatal dermatomyositis 0 trials
- Neonatal scleroderma 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Jaccoud syndrome 0 trials
-
Kimura disease 0 trials
-
Reynolds syndrome 0 trials
-
Autoimmune glomerulonephritis 0 trials
-
Autoimmune urticaria 0 trials
-
Euthyroid Graves orbitopathy 0 trials
-
Tempi syndrome 0 trials
Most studied deeper sub-types
-
Can a single CAR-T infusion reset the immune system in autoimmune disease?
Cure Recruiting nowThis early-stage trial tests a single infusion of allogeneic CAR-T cells, called RN1201, in 18 adults with autoimmune diseases that have not responded to standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells. Before the …
Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowThis study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
New vaccine trial aims to shield vulnerable children from pneumonia
Vaccine Recruiting nowThis study tests the safety and immune response of the 20-valent pneumococcal vaccine (PCV20) in children, adolescents, and young adults aged 2-25 with autoimmune rheumatic diseases like juvenile arthritis. All 114 participants will receive one dose of PCV20, and researchers will…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Vaccine
Last updated Jun 27, 2026 09:11 UTC
-
New cell therapy trial aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New injection aims to stabilize platelets in chronic ITP patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, given as a shot under the skin, can safely keep platelet counts stable in adults with chronic ITP. ITP is a condition where the immune system destroys platelets, leading to easy bruising and bleeding. The study will compare mezagitama…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a donor stem cell transplant fix broken immune systems?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells…
Phase 2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a heart drug tame rheumatoid arthritis?
Disease control Recruiting nowThis trial tests whether nicorandil, a drug currently used for heart conditions, can reduce disease activity and symptoms in people with rheumatoid arthritis. About 70 adults with moderate-to-severe RA will take either nicorandil or a placebo twice daily for three months, while c…
Phase 2/3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New combo therapy aims to stop kidney damage in membranous nephropathy
Disease control Recruiting nowThis study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Diabetes drug tirzepatide tested for type 1 in new trial
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for type 2 diabetes, can help people with type 1 diabetes. Researchers will measure how the body responds to insulin and meals before and after 6 weeks of treatment. 44 adults with type 1 diabetes who use an automated insulin pump…
Phase 2 • Sponsor: Victor Chang Cardiac Research Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a cancer drug tame rare clotting disorder?
Disease control Recruiting nowThis study tests whether daratumumab, a drug used for certain cancers, is safe for people with antiphospholipid syndrome (APS), an autoimmune disorder that raises blood clot risk. Up to 22 adults will receive weekly infusions for 8 weeks at different doses. The main goal is to ch…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a metabolic modulator help people with type 1 diabetes use insulin better?
Disease control Recruiting nowThis study tests whether a drug called AMX0035 can improve how the body responds to insulin in adults with type 1 diabetes. Participants take either AMX0035 or a placebo daily for 24 weeks. Researchers measure insulin sensitivity using a glucose clamp test and track blood sugar c…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New IVIg therapy aims to boost platelets in chronic ITP patients
Disease control Recruiting nowThis study tests a medicine called KIg 10 (intravenous immunoglobulin) in adults with chronic ITP, a condition where the immune system destroys platelets, causing bleeding and bruising. The goal is to see if KIg 10 can safely raise platelet counts and stop bleeding. About 40 peop…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can changing carb sources help tame blood sugar swings in type 1 diabetes?
Disease control Recruiting nowThis study looks at whether changing the types of carbohydrates people with type 1 diabetes eat can improve blood sugar control. Researchers will compare a diet with more whole grains and beans to one with mostly refined grains. 80 adults will be monitored to see if the diverse c…
Sponsor: Yang Tao • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Gene therapy breakthrough targets kidney disease in High-Risk patients
Disease control Recruiting nowThis study tests a new gene therapy, PS-002, for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The therapy aims to control the disease in people who are at high risk of getting worse despite current treatments. Participants receive a single dose a…
Phase 1/2 • Sponsor: Purespring Therapeutics Limited • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a single infusion of modified immune cells tame autoimmune attacks?
Disease control Recruiting nowThis early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…
Phase 1 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug trial aims to help rare immune disorder
Disease control Recruiting nowThis early-stage study tests whether belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition causing low CD4 white blood cells and increased infection risk. About 20 adults aged 18-70 with ICL and autoantibodies will receive 8 doses of belimumab intra…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a single infusion of modified immune cells tame lupus?
Disease control Recruiting nowThis early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Pig cell transplant trial aims to stop severe low blood sugar in type 1 diabetes
Disease control Recruiting nowThis early-phase study tests a new treatment called OPF-310, which uses pig islet cells enclosed in a protective capsule, for people with unstable type 1 diabetes who still experience severe low blood sugar episodes despite using an automated insulin pump and continuous glucose m…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Factory, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for giant cell arteritis patients?
Disease control Recruiting nowThis study tests whether the drug abatacept can help people with giant cell arteritis, a condition that causes inflammation in blood vessels. About 78 adults with newly diagnosed or relapsing disease will receive either abatacept or a placebo for up to 12 months. The goal is to s…
Phase 3 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for kidney disease: JADE101 trial launches
Disease control Recruiting nowThis study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…
Phase 2 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New study tracks safety of Long-Term secukinumab use
Disease control Recruiting nowThis study follows 1,000 patients with autoimmune or inflammatory conditions who have already completed a Novartis trial with secukinumab and are judged to benefit from continued treatment. Participants receive secukinumab injections to monitor long-term safety, including side ef…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can bone marrow stem cells calm lupus kidney flares?
Disease control Recruiting nowThis trial tests whether a single intravenous dose of mesenchymal stem cells, derived from bone marrow, can safely help adults with active lupus nephritis achieve a complete or partial kidney response. Participants receive either the stem cells or a placebo (saline) in a double-b…
Phase 2 • Sponsor: Red de Terapia Celular • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for kidney disease: Zigakibart's Long-Term safety under study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells tame autoimmune disease?
Disease control Recruiting nowThis early-phase trial is testing whether a single infusion of engineered immune cells, called CAR NK cells, can safely and effectively treat people with moderate to severe autoimmune diseases that have not improved with standard treatment. The study will enroll 15 adults and wil…
Early phase 1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to shield autoimmune patients from Life-Threatening infections
Disease control Recruiting nowThis study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can an antiviral drug stop RSV in vulnerable patients?
Disease control Recruiting nowThis study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to boost immune cells in rare blood disorder
Disease control Recruiting nowThis Phase 3 study tests whether the drug mavorixafor can reduce serious infections and increase neutrophil levels in people with chronic neutropenia—a condition where the body doesn't make enough infection-fighting white blood cells. About 176 participants will receive either ma…
Phase 3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Phase 1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug BHV-1300 tested for Graves' disease safety
Disease control Recruiting nowThis early study is testing a new drug called BHV-1300 in 15 people with Graves' disease. The main goal is to see if the drug is safe and to check how it affects certain markers of the disease. This is a phase 1 trial, so it's one of the first steps in testing this treatment in h…
Phase 1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug trial aims to ease muscle weakness in myasthenia gravis
Disease control Recruiting nowThis study tests an investigational drug called IMVT-1402 in 231 adults with mild to severe generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it improves daily activities and muscle strength. The goal i…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Engineered immune cells take on lupus, scleroderma, and Sjogren's
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowThis study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard immunosuppressive drugs for generalized myasthenia gravis. About 66 adults who have not responded to at least two prior therapies will be randomly assigned to receive either …
Phase 2/3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…
Sponsor: Liang Zou • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Pausing arthritis drug may boost pneumonia Shot's power
Disease control Recruiting nowThis study tests whether temporarily stopping methotrexate for 2 weeks after receiving a pneumonia vaccine (PCV20) helps the vaccine work better in adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus. About 192 participants with stable, low disease activi…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New RA drug BMS-986454 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called BMS-986454 in 46 adults with rheumatoid arthritis who did not fully respond to methotrexate. The main goal is to check the drug's safety, tolerability, and how it moves through the body. Participants will receive either the drug…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental cell therapy called NEUK203-215 in adults aged 18-65 with severe autoimmune diseases like lupus or scleroderma that have not responded to other treatments. The therapy uses immune cells from a healthy donor, engineered to target and at…
Early phase 1 • Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Donor immune cells aim to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a stem cell transplant tame VEXAS syndrome?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a donor can help people with VEXAS syndrome, a rare autoinflammatory disease. Participants receive donor stem cells after drugs to prepare their bone marrow. The goal is to see if the transplant can reverse symptoms and allow p…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could CAR T-Cells tame tough lupus? tiny trial aims to find out
Disease control Recruiting nowThis early-stage trial will test whether a personalized immune cell therapy called CAR T-cells is safe for 8 adults with severe lupus that hasn't improved with standard treatments. Participants will receive a single infusion of their own genetically modified cells after a short c…
Phase 1 • Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Cord blood transplants made more accessible for thousands with blood cancers
Disease control Recruiting nowThis study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized immune cells take aim at Drug-Resistant eye virus
Disease control Recruiting nowThis study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial ai…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New RA drug enters first human safety trial
Disease control Recruiting nowThis study tests a new medicine called SBT777101 in 24 people with moderate-to-severe rheumatoid arthritis (RA). It is the first time this drug is given to humans, so the main goal is to check safety and side effects. Participants receive a single dose, and the dose is increased …
Phase 1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to calm immune attacks on kidneys
Disease control Recruiting nowThis Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…
Phase 2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New blood filter could improve treatment for autoimmune diseases
Disease control Recruiting nowThis study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy takes on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…
Phase 1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Early phase 1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug shows promise for kidney disease patients
Disease control Recruiting nowThis study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damag…
Phase 2 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Early phase 1 • Sponsor: Vivacta Biotechnology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug S-4321 aims to tame overactive immune system
Disease control Recruiting nowThis early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…
Phase 1 • Sponsor: Seismic Therapeutic AU Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowThis study tests two types of engineered immune cells (CAR T cells) in 40 adults with active pemphigus vulgaris, a painful blistering skin condition. The cells are designed to target and reduce the faulty immune cells that attack the skin. The main goal is to check safety and fin…
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug GT801 tested for tough autoimmune cases
Disease control Recruiting nowThis early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a cholesterol drug and vitamin ease thyroid eye disease?
Disease control Recruiting nowThis study tests whether taking a statin (atorvastatin) and vitamin D can calm inflammation and reduce eye bulging in people with active thyroid eye disease. 120 adults will be randomly assigned to standard care alone, statin plus standard care, vitamin D plus standard care, or b…
Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Steroid tapering showdown: quick stop vs. slow wean in inflammation patients
Disease control Recruiting nowThis study looks at whether people with inflammatory or autoimmune diseases can safely stop taking steroids (like prednisone) right away instead of slowly reducing the dose over 4 weeks. The goal is to see if stopping quickly leads to more hospital visits or adrenal crises. About…
Phase 4 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Frozen testicle tissue may help men have kids after cancer
Disease control Recruiting nowThis study tests a new way to help men who lost fertility due to cancer or autoimmune treatments. Doctors will transplant the patient's own frozen testicular tissue back into them. The goal is to see if it is safe and can restart sperm production.
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a single infusion of supercharged immune cells tame incurable autoimmune diseases?
Disease control Recruiting nowThis early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …
Sponsor: LiangZou • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on lupus and scleroderma
Disease control Recruiting nowThis early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New injection aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New arthritis drug for kids shows promise in early trial
Disease control Recruiting nowThis study is testing a drug called olokizumab in children aged 2 to 18 with active juvenile idiopathic arthritis. The drug is given as a shot under the skin every 4 weeks. Researchers want to see how the drug moves through the body, if it helps control arthritis symptoms, and if…
Phase 2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for IgG4 patients: which drug combo works best?
Disease control Recruiting nowThis study tests two treatment plans for people with IgG4-related disease affecting superficial organs like glands or skin. One group gets prednisone plus iguratimod, the other gets prednisone plus leflunomide. Over 12 months, researchers will track how many patients have a relap…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New injection for autoimmune diseases takes first step in human testing
Disease control Recruiting nowThis early-stage study tests a new medicine called GenSci136 in 48 healthy adults in China. The goal is to check if a single shot is safe and how the body processes it. This is a first step toward possibly treating autoimmune diseases, where the immune system attacks the body.
Phase 1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
MRNA therapy takes on autoimmune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new mRNA-based treatment (ABO2203) for people with autoimmune diseases that haven't improved with standard care. The therapy works by directing the body's immune cells to attack and control overactive immune cells causing the disease. The study will…
Early phase 1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental CAR-T shot targets three tough autoimmune diseases
Disease control Recruiting nowThis early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental CAR t therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AFN50 for people with autoimmune diseases that haven't responded to standard therapies. AFN50 is a type of CAR T-cell therapy designed to target and destroy faulty immune cells. The study will enroll 18 adults to check if the tr…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New biologic STR-P004 tested for tough autoimmune cases
Disease control Recruiting nowThis early study tests the safety of a new biologic drug called STR-P004 in 39 adults with autoimmune diseases that have not responded to standard treatments. Participants receive the drug by IV infusion, and researchers monitor for side effects and how the drug behaves in the bo…
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could starting pills earlier improve treatment for rare blood disorder?
Disease control Recruiting nowThis study tests whether starting two oral medications (cyclosporine and eltrombopag) earlier than usual is safe and feasible for people with severe aplastic anemia, a rare condition where the immune system attacks bone marrow. Participants aged 3 and older will take these pills …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New biologic GR1803 aims to tame lupus in early trial
Disease control Recruiting nowThis study tests a new biologic drug called GR1803 in 44 people with systemic lupus erythematosus, an autoimmune disease. The main goal is to check safety and see if the drug can control lupus activity. Participants must have moderate to severe lupus and have tried standard treat…
Phase 1/2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New injection aims to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new injection called AFN50 in 18 adults with autoimmune diseases like lupus. The main goal is to check safety and see how the body reacts, including changes in immune cells. Participants must have active disease despite standard treatments.
Early phase 1 • Sponsor: AlphaNa Bioscience Company Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Immune reset: CAR-T cells take on lupus and more
Disease control Recruiting nowThis early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Turmeric power: could curcumin nanogels replace steroids for a painful mouth condition?
Disease control Recruiting nowThis study compares curcumin nanogels (a natural turmeric extract) to a standard steroid paste for treating atrophic-erosive oral lichen planus, a chronic inflammatory mouth condition. Thirty adults will apply either treatment three times daily for four weeks. Researchers will me…
Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …
Phase 1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Phase 1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental CAR-T therapy takes on progressive MS
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells …
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Universal CAR-T cells take on lupus and more in early trial
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…
Early phase 1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could CAR t-cells tame myasthenia gravis? early trial launches
Disease control Recruiting nowThis early-phase study tests a new treatment called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis, a condition that causes muscle weakness. Anito-cel is a type of CAR T-cell therapy that targets BCMA, a protein on certain immune cells. The tr…
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment for children with B cell-related autoimmune diseases like lupus and kidney disease. The therapy uses specially engineered natural killer (NK) cells that target and destroy faulty immune cells. Only 12 children will take part, and …
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New RNA therapy aims to tame Out-of-Control immune system
Disease control Recruiting nowThis early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…
Early phase 1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a quick strike drug stop MS in its tracks?
Disease control Recruiting nowThis study tests whether giving the drug natalizumab (Tyruko) within two weeks of first MS symptoms can help repair nerve damage. Forty adults with a first episode of MS-like inflammation will receive either the drug or a placebo. The main goal is to see if early treatment improv…
Phase 2 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental CAR-T therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…
Early phase 1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy (CAR-NK cells) in 36 children with B-cell-related autoimmune diseases like lupus and certain kidney diseases. The therapy uses specially designed immune cells to target and potentially control the overactive immune syst…
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a website help tame type 1 diabetes? new study seeks answers
Disease control Recruiting nowThis study tests whether an online training and support platform can help adults with type 1 diabetes better manage their blood sugar and well-being. About 322 participants across Canada will use the platform for 12 months, either as part of their usual clinic care or on their ow…
Sponsor: McGill University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New online tool aims to ease tough transition for teens with diabetes
Disease control Recruiting nowThis study tests whether an online training and peer support platform (Support-t) helps teens with type 1 diabetes prepare for the move from pediatric to adult healthcare. About 200 teens aged 14-16 will either use the platform plus usual care or just usual care. The main goal is…
Sponsor: Anne-Sophie Brazeau • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immune reset: CAR-T therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…
Sponsor: ShenZhen Cell Valley • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a simple Under-the-Tongue spray protect kidneys?
Disease control Recruiting nowThis study tests a liquid medication called ACE Reno, taken under the tongue four times daily for 12 weeks, in 300 adults with chronic kidney disease from diabetes, high blood pressure, autoimmune disorders, or other causes. The goal is to see if it safely reduces protein in the …
Phase 4 • Sponsor: Ace Cells Lab Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immune reset: CAR-T therapy takes on lupus, myositis, and ITP
Disease control Recruiting nowThis early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune syste…
Early phase 1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:04 UTC
-
New drug targets Antibody-Producing cells in brain inflammation
Disease control Recruiting nowThis phase 2 trial tests whether bortezomib, a drug that targets antibody-producing cells, can help people with severe autoimmune encephalitis. In this condition, the body's own antibodies attack the brain. The study will enroll 50 adults who have already tried another treatment …
Phase 2 • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:23 UTC
-
Experimental CAR-T therapy targets stubborn autoimmune disease
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called anti-BCMA-CD19 CAR-T cells in 9 adults with IgG4-related disease that hasn't responded to standard treatments. Participants receive an infusion of their own modified immune cells after a short course of chemotherapy. The…
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:38 UTC
-
Brain scan clues may sharpen MS diagnosis
Diagnosis Recruiting nowThis study follows 40 people with multiple sclerosis (MS) for 48 months to see if two MRI markers—the central vein sign and paramagnetic rim lesions—can improve how doctors diagnose and monitor the disease. Participants will have brain scans and disability tests at the end of the…
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
Can the shingles vaccine protect those with autoimmune conditions?
Prevention Recruiting nowThis study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
New monthly shot could ease Sjögren's dry mouth
Symptom relief Recruiting nowThis phase 3 study tests whether ianalumab, given as a monthly injection, can reduce dry mouth and other symptoms in people with Sjögren's disease who have a high symptom burden. About 570 adults will receive either the drug or a placebo for 52 weeks. The main goal is to see if t…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Could a steroid ease autism symptoms? small trial aims to find out
Symptom relief Recruiting nowThis early-phase trial tests whether the steroid prednisone can improve core autism symptoms in 32 adult males with an immune-mediated subtype of autism. Participants take prednisone or a placebo daily for 16 weeks, with regular check-ins and questionnaires. The goal is to see if…
Early phase 1 • Sponsor: Christopher John McDougle, M.D. • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Strumming for the brain: could ukulele lessons sharpen minds in MS?
Symptom relief Recruiting nowThis study tests whether a 12-week online ukulele learning program, called Music-4-MS, can improve cognitive function in people with multiple sclerosis (MS). Half the participants will learn to play the ukulele, while the other half will simply listen to music they enjoy. The goa…
Sponsor: University of Texas at Austin • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Meat or fat? diet study aims to tame IBD and arthritis symptoms
Symptom relief Recruiting nowThis study tests whether a ketogenic (low-carb, high-fat) or carnivore (all meat) diet can improve quality of life and reduce symptoms in adults with inflammatory bowel disease (Crohn's or ulcerative colitis) or rheumatoid arthritis. Participants are randomly assigned to one of t…
Sponsor: Fuller Research Foundation • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists hunt for genetic clues to mysterious immune diseases
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of inherited immune problems that affect white blood cells called lymphocytes. Researchers will review medical records and collect blood samples from up to 5,000 people with suspected immune disorders, as well as their relatives. The goa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive gene hunt aims to unlock secrets of immune disorders
Knowledge-focused Recruiting nowThis study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
20,000 volunteers needed to decode immune disease genetics
Knowledge-focused Recruiting nowThis study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track rare immune disease to unlock its secrets
Knowledge-focused Recruiting nowThis study follows people with autoimmune lymphoproliferative syndrome (ALPS) and their relatives over many years. Researchers will collect blood and tissue samples, track symptoms, and study genetics to better understand why the immune system attacks the body. The goal is to lea…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
500-Patient study aims to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 500 children and adults with rare genetic disorders called type I interferonopathies, which cause severe inflammation and neurological problems. Researchers will track how the disease progresses over time and look for biological markers to improve diagnosis and…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
New registry aims to uncover risks of common transplant drug in pregnancy
Knowledge-focused Recruiting nowThis registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the dru…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists seek hidden causes of chronic lung infections
Knowledge-focused Recruiting nowThis study follows 900 people with bronchiectasis—a condition where airways are damaged and prone to infection—to learn why they get sick repeatedly. Researchers will collect medical history, lung function tests, and blood, urine, and sputum samples from patients and their family…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a simple blood test unlock the secrets of brain autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Genetic hunt for hidden causes of mysterious inflammatory diseases
Knowledge-focused Recruiting nowThis study aims to better understand VEXAS syndrome and other autoinflammatory conditions by analyzing participants' DNA from blood, saliva, or skin samples. Researchers hope to discover new genetic variants that cause or contribute to these diseases. The study enrolls people of …
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Scientists investigate why immunotherapy attacks the nervous system
Knowledge-focused Recruiting nowThis study looks at why some cancer patients develop neurological problems after receiving immunotherapy drugs called checkpoint inhibitors. Researchers will analyze spinal fluid and blood from 160 participants to find immune cells that may mistakenly attack the nervous system. T…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
500-Person biobank aims to unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Protein clue could unlock new autoimmune treatments
Knowledge-focused Recruiting nowThis study is measuring a protein called STIM1 on the surface of immune cells in 670 people with various autoimmune diseases. The goal is to find which diseases have high levels of this protein, which could help researchers develop new antibody-based treatments. Participants prov…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Lupus patients enrolled in major Long-Term observation study
Knowledge-focused Recruiting nowThis study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could your environment trigger this rare muscle disease?
Knowledge-focused Recruiting nowThis study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New autoimmune drug candidate takes first step in human tests
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called DWP212525 in 84 healthy adults aged 19 to 55. The main goal is to check safety and how the drug moves through the body. It is the first step in developing a possible treatment for autoimmune diseases.
Phase 1 • Sponsor: Daewoong Pharmaceutical Co. LTD. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Scientists hunt for hidden antibodies in severe seizure disorders
Knowledge-focused Recruiting nowThis study collects blood, spinal fluid, and brain tissue from 400 people with severe seizures (status epilepticus) or epilepsy linked to brain inflammation (dysimmune encephalitis), plus control patients. Researchers aim to find antibodies and markers of nerve cell death that co…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists dive deep into immune cells to unlock type 1 diabetes secrets
Knowledge-focused Recruiting nowThis study is collecting blood samples from 1,160 people with and without type 1 diabetes to analyze the immune cells that mistakenly attack the pancreas. The goal is to better understand how these cells work, which could lead to improved treatments or prevention strategies in th…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New tool aims to help melanoma patients with autoimmune conditions navigate treatment decisions
Knowledge-focused Recruiting nowThis study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Could iron be the key to understanding lupus?
Knowledge-focused Recruiting nowThis study looks at how a type of cell death called ferroptosis, which is driven by iron, might play a role in lupus. Researchers will take blood samples from 120 people with lupus and compare them to people with other autoimmune diseases. The goal is to find new clues for future…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New blood marker may predict Sjögren's Flare-Ups
Knowledge-focused Recruiting nowThis study is looking for a better way to track disease activity in people with primary Sjögren's syndrome, a chronic autoimmune disease that causes dryness and can affect organs. Researchers will test a new blood marker called anti-Ro/SSA IgE in 185 participants to see if it is …
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study tests simple tools to boost COVID-19 shots in minority communities with arthritis
Knowledge-focused Recruiting nowThis study tests whether watching videos about COVID-19 vaccination experiences and receiving phone support can increase vaccine uptake among Black and Latinx adults with rheumatic diseases. Researchers will enroll 1,170 participants from rheumatology clinics. The goal is to find…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to cut risky pills for seniors with arthritis
Knowledge-focused Recruiting nowThis study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Tiny gluten doses spark immune changes in kids with celiac disease
Knowledge-focused Recruiting nowThis study looks at how the immune system of children with celiac disease responds to tiny, controlled amounts of gluten. About 51 kids on a strict gluten-free diet will get either a placebo, a small dose (50 mg), or a larger dose (5 g) of gluten daily for three days. Researchers…
Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New autoimmune drug JANX011 enters first human safety trial
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called JANX011 in 60 healthy adults. Researchers will give a single dose and monitor for side effects. The goal is to gather initial safety data before testing in people with autoimmune diseases.
Early phase 1 • Sponsor: Janux Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Frozen hope: new study banks testicular tissue for boys at risk of infertility
Knowledge-focused Recruiting nowThis study collects and freezes testicular tissue from boys and young men who are at risk of becoming infertile due to cancer, autoimmune disorders, or their treatments. The tissue is stored in a research bank, with the hope that future medical advances will allow it to be used t…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists dive deep into joint tissue to unlock secrets of rare arthritis
Knowledge-focused Recruiting nowThis study aims to better understand rare forms of inflammatory arthritis, including those linked to other autoimmune diseases or cancer immunotherapy. Researchers will analyze joint tissue samples from 100 adults to compare the immune cells and molecules involved. The goal is to…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Your genes, your meds: 1200-Patient study tests smarter prescribing
Knowledge-focused Recruiting nowThis study collects DNA from 1200 patients receiving routine care at the University of Chicago. Researchers look for genetic differences that might affect how well a drug works or how likely it is to cause side effects. The goal is to see if giving this genetic information to doc…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New study offers hope for fertility preservation in young patients facing cancer or autoimmune treatments
Knowledge-focused Recruiting nowThis study aims to preserve fertility for up to 500 female patients under 40 who are at risk of infertility due to cancer, autoimmune diseases, or their treatments. Participants will have an ovary surgically removed and frozen for potential future use. Researchers will also study…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients
Knowledge-focused Recruiting nowThis study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…
Phase 3 • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Massive new registry aims to unlock secrets of biologic drugs
Knowledge-focused Recruiting nowThis study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Massive study seeks genetic roots of allergies and immune problems
Knowledge-focused Recruiting nowThis study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New study aims to predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowThis study collects medical information and biological samples (blood, tissue, stool) from 1,000 cancer patients receiving immune checkpoint inhibitors. The goal is to understand why some patients develop immune-related side effects and find ways to predict and manage them. Parti…
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Blood cell collection could pave way for new immune therapies
Knowledge-focused Recruiting nowThis study collects white blood cells from up to 10 healthy volunteers and patients with autoimmune diseases, inflammation, or liver transplant. The goal is to analyze these cells to help develop engineered regulatory T cell (Treg) therapies. No treatment is given; it is a resear…
Sponsor: Quell Therapeutics Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Massive study aims to unlock secrets of brain inflammation diseases
Knowledge-focused Recruiting nowThis research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…
Sponsor: Brain Inflammation Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Family study aims to unlock scleroderma secrets
Knowledge-focused Recruiting nowThis study looks at 20 adults with systemic scleroderma who have a family history of the disease. Researchers will describe their symptoms and progression to find clues about how the disease works and identify markers that could lead to new treatments. The goal is to learn more, …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New study investigates if smart insulin pumps reduce disordered eating in diabetes
Knowledge-focused Recruiting nowThis study looks at whether newer automated insulin delivery systems help people with type 1 diabetes have healthier eating behaviors. Researchers will survey over 100 youth and adults across Canada about their eating habits and blood sugar control. The goal is to understand if t…
Sponsor: McGill University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New registry aims to unlock secrets of autoimmune disease in pregnancy
Knowledge-focused Recruiting nowThis registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Scientists investigate why immunotherapy causes autoimmune problems in some cancer patients
Knowledge-focused Recruiting nowThis study aims to understand why some cancer patients develop autoimmune side effects when treated with immune checkpoint inhibitors. Researchers will analyze blood cells and genetics from 600 participants to identify features linked to these side effects. The goal is to improve…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study probes why some babies develop eczema: Self-Antibodies under the microscope
Knowledge-focused Recruiting nowThis study looks at whether babies born with certain self-reactive antibodies are more likely to develop eczema. Researchers will test umbilical cord blood from 500 newborns—some with a family history of allergies or eczema, some without—and follow them for two years. The goal is…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists hunt for genetic clues in rare childhood immune disorders
Knowledge-focused Recruiting nowThis study is not a treatment trial. It aims to collect blood samples from 400 children and their relatives who have rare autoimmune or autoinflammatory diseases (like lupus or juvenile arthritis). Researchers will analyze the samples to find genetic mutations that cause these co…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Major study launches to unravel rare genetic diseases affecting immunity and the brain
Knowledge-focused Recruiting nowThis study aims to learn more about rare genetic diseases that affect both the immune system and the nervous system. Researchers will collect medical information and samples from 1,000 participants, including patients, their relatives, and healthy volunteers. The goal is to bette…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Scientists probe immune link to migraine in autoimmune patients
Knowledge-focused Recruiting nowThis study looks at how immune cells and inflammatory molecules differ in people with migraine, especially those who also have autoimmune diseases like multiple sclerosis, rheumatoid arthritis, or endometriosis. Researchers will compare blood samples from 396 women to measure reg…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Massive study aims to unlock secrets of rare blood disorder
Knowledge-focused Recruiting nowThis study reviews medical records from over 1,200 people with immune thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. The goal is to understand long-term health problems, such as heart disease and thinking issues, that survivors face. By an…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC